{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T13:10:10Z","timestamp":1745932210001,"version":"3.40.4"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bulcan.2025.02.015","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:20:48Z","timestamp":1743232848000},"page":"454-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab en association \u00e0 la chimioth\u00e9rapie dans le m\u00e9soth\u00e9liome pleural non r\u00e9s\u00e9cable en premi\u00e8re ligne"],"prefix":"10.1016","volume":"112","author":[{"given":"Sofiene","family":"Fendri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gobbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2025.02.015_bib0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/carcin\/bgz004","article-title":"Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database","volume":"40","author":"Van Gerwen","year":"2019","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.bulcan.2025.02.015_bib0040","first-page":"100280","article-title":"A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern","volume":"3","author":"Kerrigan","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"10026","key":"10.1016\/j.bulcan.2025.02.015_bib0045","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3\u00a0trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2025.02.015_bib0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bulcan.2021.07.010","article-title":"New MAA: first-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma","volume":"109","author":"Laune","year":"2022","journal-title":"Bull Cancer (Paris)"},{"issue":"10272","key":"10.1016\/j.bulcan.2025.02.015_bib0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3\u00a0trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"10419","key":"10.1016\/j.bulcan.2025.02.015_bib0030","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125001316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125001316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T12:45:29Z","timestamp":1745930729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125001316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0007455125001316"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.02.015","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab en association \u00e0 la chimioth\u00e9rapie dans le m\u00e9soth\u00e9liome pleural non r\u00e9s\u00e9cable en premi\u00e8re ligne","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}